Topical 0.5% Timolol Maleate for Superficial Infantile Hemangioma Treatment

Infantile hemangioma (IH) is a common type of benign vascular tumor found in children. This condition typically grows rapidly within the first year of life and then starts to shrink on its own. However, it may lead to cosmetic concerns. Early treatment of superficial IH can help minimize the risk of lasting aesthetic issues. One such treatment is topical timolol, a non-selective beta-blocker, which has shown promising results in terms of effectiveness and safety. However, most studies conducted so far have been small or case-specific. This study aims to evaluate the efficacy and safety of a 0.5% timolol maleate solution for treating superficial IH in a larger, more controlled setting. Participants in this study will receive topical timolol treatment for a minimum of 6 months. They will be instructed to apply 1-2 drops of the timolol solution onto the affected area four times a day, gently rubbing it over the entire lesion. Photographs of the lesion will be taken at the beginning of the study and during every monthly visit to monitor progress. Two independent investigators will evaluate the treatment's effectiveness by assessing changes in lesion size and color using a visual analogue scale. The primary outcome is to determine the efficacy of the 0.5% timolol maleate solution in treating infantile hemangioma compared to a placebo.